Glucagon receptor antagonist and GIP agonist combination for diet induced obese mice.

L McShane, Nigel Irwin, D O'Flynn, Z Franklin, C Hewage, Finbarr O'Harte

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Ablation of glucagon receptor signalling represents a potential treatment option for type 2 diabetes (T2DM). Additionally, activation of glucose-dependent insulinotropic polypeptide (GIP) receptor signalling also holds therapeutic promise for T2DM. Therefore, the present study examined both independent and combined metabolic actions of desHis1Pro4Glu9(Lys12PAL)-glucagon (glucagon receptor antagonist) and D-Ala2GIP (GIP receptor agonist), in diet induced obese mice. Glucagon receptor binding has been linked to alpha-helical structure and desHis1Pro4Glu9(Lys12PAL)-glucagon displayed enhanced alpha-helical content compared to native glucagon. In clonal pancreatic BRIN-BD11 beta-cells, desHis1Pro4Glu9(Lys12PAL)-glucagon was devoid of any insulinotropic or cAMP generating actions, and did not impede D-Ala2GIP-mediated (p
LanguageEnglish
Pages319-330
JournalJournal of Endrocrinology
Volume229
Early online date20 Apr 2016
DOIs
Publication statusPublished - 1 Jun 2016

Fingerprint

Glucagon Receptors
Obese Mice
Glucagon
Diet
Glucose
Peptides
Type 2 Diabetes Mellitus

Keywords

  • glucagon
  • glucose-dependent insulinotropic polypeptide (GIP)
  • glucose 25 homeostasis
  • insulin secretion
  • insulin sensitivity
  • glucagon receptor antagonist
  • GIP receptor agonist
  • diet nduced obese diabetic mice

Cite this

@article{fcf299bc77984bef8efe07fa7efd21e4,
title = "Glucagon receptor antagonist and GIP agonist combination for diet induced obese mice.",
abstract = "Ablation of glucagon receptor signalling represents a potential treatment option for type 2 diabetes (T2DM). Additionally, activation of glucose-dependent insulinotropic polypeptide (GIP) receptor signalling also holds therapeutic promise for T2DM. Therefore, the present study examined both independent and combined metabolic actions of desHis1Pro4Glu9(Lys12PAL)-glucagon (glucagon receptor antagonist) and D-Ala2GIP (GIP receptor agonist), in diet induced obese mice. Glucagon receptor binding has been linked to alpha-helical structure and desHis1Pro4Glu9(Lys12PAL)-glucagon displayed enhanced alpha-helical content compared to native glucagon. In clonal pancreatic BRIN-BD11 beta-cells, desHis1Pro4Glu9(Lys12PAL)-glucagon was devoid of any insulinotropic or cAMP generating actions, and did not impede D-Ala2GIP-mediated (p",
keywords = "glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucose 25 homeostasis, insulin secretion, insulin sensitivity, glucagon receptor antagonist, GIP receptor agonist, diet nduced obese diabetic mice",
author = "L McShane and Nigel Irwin and D O'Flynn and Z Franklin and C Hewage and Finbarr O'Harte",
year = "2016",
month = "6",
day = "1",
doi = "10.1530/JOE-15-0463",
language = "English",
volume = "229",
pages = "319--330",
journal = "Journal of Endrocrinology",
issn = "0022-0795",

}

Glucagon receptor antagonist and GIP agonist combination for diet induced obese mice. / McShane, L; Irwin, Nigel; O'Flynn, D; Franklin, Z; Hewage, C; O'Harte, Finbarr.

In: Journal of Endrocrinology, Vol. 229, 01.06.2016, p. 319-330.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Glucagon receptor antagonist and GIP agonist combination for diet induced obese mice.

AU - McShane, L

AU - Irwin, Nigel

AU - O'Flynn, D

AU - Franklin, Z

AU - Hewage, C

AU - O'Harte, Finbarr

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Ablation of glucagon receptor signalling represents a potential treatment option for type 2 diabetes (T2DM). Additionally, activation of glucose-dependent insulinotropic polypeptide (GIP) receptor signalling also holds therapeutic promise for T2DM. Therefore, the present study examined both independent and combined metabolic actions of desHis1Pro4Glu9(Lys12PAL)-glucagon (glucagon receptor antagonist) and D-Ala2GIP (GIP receptor agonist), in diet induced obese mice. Glucagon receptor binding has been linked to alpha-helical structure and desHis1Pro4Glu9(Lys12PAL)-glucagon displayed enhanced alpha-helical content compared to native glucagon. In clonal pancreatic BRIN-BD11 beta-cells, desHis1Pro4Glu9(Lys12PAL)-glucagon was devoid of any insulinotropic or cAMP generating actions, and did not impede D-Ala2GIP-mediated (p

AB - Ablation of glucagon receptor signalling represents a potential treatment option for type 2 diabetes (T2DM). Additionally, activation of glucose-dependent insulinotropic polypeptide (GIP) receptor signalling also holds therapeutic promise for T2DM. Therefore, the present study examined both independent and combined metabolic actions of desHis1Pro4Glu9(Lys12PAL)-glucagon (glucagon receptor antagonist) and D-Ala2GIP (GIP receptor agonist), in diet induced obese mice. Glucagon receptor binding has been linked to alpha-helical structure and desHis1Pro4Glu9(Lys12PAL)-glucagon displayed enhanced alpha-helical content compared to native glucagon. In clonal pancreatic BRIN-BD11 beta-cells, desHis1Pro4Glu9(Lys12PAL)-glucagon was devoid of any insulinotropic or cAMP generating actions, and did not impede D-Ala2GIP-mediated (p

KW - glucagon

KW - glucose-dependent insulinotropic polypeptide (GIP)

KW - glucose 25 homeostasis

KW - insulin secretion

KW - insulin sensitivity

KW - glucagon receptor antagonist

KW - GIP receptor agonist

KW - diet nduced obese diabetic mice

U2 - 10.1530/JOE-15-0463

DO - 10.1530/JOE-15-0463

M3 - Article

VL - 229

SP - 319

EP - 330

JO - Journal of Endrocrinology

T2 - Journal of Endrocrinology

JF - Journal of Endrocrinology

SN - 0022-0795

ER -